BACKGROUND: In Korea, endoscopic submucosal dissection (ESD) has been widely accepted for the treatment of early gastric cancers (EGCs). However, the understanding of the long-term clinical outcome of ESD for EGC remains insufficient. Therefore, the aim of the present study was to assess the long-term clinical outcome and efficacy of ESD for the treatment of EGCs, including the clinical application of the expanded criteria for ESD. METHODS: From January 2006 to December 2010, a total of 515 patients with 522 EGCs were treated by ESD in our hospital; study enrollment was based on the expanded criteria. Comparisons of resectability (en bloc or piecemeal resection), curability (curative or non-curative), and complications (bleeding and perforation) between the standard and expanded groups were assessed. Thereafter, 336 patients with 342 EGCs were finally included in a long-term analysis of local tumor recurrence, development of synchronous and metachronous cancers, and overall and disease-specific survival rates. RESULTS: En bloc and curative resection rates of 96.7 % and 88.3 %, respectively, were achieved. The curative resection rate was significantly lower in the expanded group than in the standard group (82.1 % vs. 91.5 %, p = 0.001). During a median follow-up of 24 months, the local tumor recurrence rate was also higher in the expanded group than in the standard group (7.0 % vs. 1.8 %, p = 0.025). Local recurrence was more frequent in lesions with non-curative resection than in those with curative resection (20.0 % vs. 1.3 %, p < 0.001). The 5-year overall and disease-specific survival rates were 88 % and 100 %, respectively; the difference between the standard and expanded groups was not significant (p = 0.834). CONCLUSIONS: ESD appears to be a feasible and effective method for treating EGCs, based on the standard and expanded criteria. Close follow-up surveillance, after ESD, should be standard for all patients.
BACKGROUND: In Korea, endoscopic submucosal dissection (ESD) has been widely accepted for the treatment of early gastric cancers (EGCs). However, the understanding of the long-term clinical outcome of ESD for EGC remains insufficient. Therefore, the aim of the present study was to assess the long-term clinical outcome and efficacy of ESD for the treatment of EGCs, including the clinical application of the expanded criteria for ESD. METHODS: From January 2006 to December 2010, a total of 515 patients with 522 EGCs were treated by ESD in our hospital; study enrollment was based on the expanded criteria. Comparisons of resectability (en bloc or piecemeal resection), curability (curative or non-curative), and complications (bleeding and perforation) between the standard and expanded groups were assessed. Thereafter, 336 patients with 342 EGCs were finally included in a long-term analysis of local tumor recurrence, development of synchronous and metachronous cancers, and overall and disease-specific survival rates. RESULTS: En bloc and curative resection rates of 96.7 % and 88.3 %, respectively, were achieved. The curative resection rate was significantly lower in the expanded group than in the standard group (82.1 % vs. 91.5 %, p = 0.001). During a median follow-up of 24 months, the local tumor recurrence rate was also higher in the expanded group than in the standard group (7.0 % vs. 1.8 %, p = 0.025). Local recurrence was more frequent in lesions with non-curative resection than in those with curative resection (20.0 % vs. 1.3 %, p < 0.001). The 5-year overall and disease-specific survival rates were 88 % and 100 %, respectively; the difference between the standard and expanded groups was not significant (p = 0.834). CONCLUSIONS: ESD appears to be a feasible and effective method for treating EGCs, based on the standard and expanded criteria. Close follow-up surveillance, after ESD, should be standard for all patients.
Authors: S Oka; S Tanaka; I Kaneko; R Mouri; M Hirata; H Kanao; T Kawamura; S Yoshida; M Yoshihara; K Chayama Journal: Endoscopy Date: 2006-10 Impact factor: 10.093
Authors: Su Youn Nam; Il Ju Choi; Kyung Woo Park; Chan Gyoo Kim; Jong Yeul Lee; Myeong-Cherl Kook; Jong Seok Lee; Sook Ryun Park; Jun Ho Lee; Keun Won Ryu; Young-Woo Kim Journal: Eur J Gastroenterol Hepatol Date: 2009-08 Impact factor: 2.566
Authors: H Isomoto; S Shikuwa; N Yamaguchi; E Fukuda; K Ikeda; H Nishiyama; K Ohnita; Y Mizuta; J Shiozawa; S Kohno Journal: Gut Date: 2008-11-10 Impact factor: 23.059
Authors: Chang Seok Bang; Gwang Ho Baik; In Soo Shin; Jing Bong Kim; Ki Tae Suk; Jai Hoon Yoon; Yeon Soo Kim; Dong Joon Kim; Woon Geon Shin; Kyung Ho Kim; Hak Yang Kim; Hyun Lim; Ho Seok Kang; Jong Hyeok Kim; Jin Bae Kim; Sung Won Jung; Sea Hyub Kae; Hyun Joo Jang; Min Ho Choi Journal: World J Gastroenterol Date: 2015-05-21 Impact factor: 5.742
Authors: Jae Pil Han; Su Jin Hong; Hee Kyung Kim; Yun Nah Lee; Tae Hee Lee; Bong Min Ko; Joo Young Cho Journal: Surg Endosc Date: 2015-04-01 Impact factor: 4.584
Authors: Hyun Jung Lee; Gwang Ha Kim; Do Youn Park; Young Keum Kim; Hye Kyung Jeon; Bong Eun Lee; Geun Am Song Journal: Gastric Cancer Date: 2017-03-07 Impact factor: 7.370